Leadership & Pay ·
Unicycive Therapeutics appoints Meredith S. Manning as independent director and chair of three committees
UNCYUnicycive Therapeutics, Inc.
Unicycive Therapeutics appointed Meredith S. Manning as an independent director effective October 1, 2026, assigning her to the Audit, Compensation, and Nominating committees where she will serve as chair. The company resubmitted its New Drug Application for oxylanthanum carbonate, addressing prior Complete Response Letters by adding CMC data from a new manufacturing vendor with FDA 'No Action Indicated' status. Unicycive anticipates FDA acceptance within 30 days and expects a PDUFA date six months post-resubmission, while maintaining cash reserves of $61.4 million to support operations into the second half of 2027. The company operates in the biotechnology industry, developing therapies for kidney diseases.